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Abstract The synthesis of ruthenium(II) and osmium(II)
arene complexes with the closely related indolo[3,2-c]-
quinolines N-(11H-indolo[3,2-c]quinolin-6-yl)-ethane-1,2-
diamine (L
1) and N0-(11H-indolo[3,2-c]quinolin-6-yl)-
N,N-dimethylethane-1,2-diamine (L
2) and indolo[3,2-d]-
benzazepines N-(7,12-dihydroindolo-[3,2-d][1]benzazepin-
6-yl)-ethane-1,2-diamine (L
3) and N0-(7,12-dihydroindolo-
[3,2-d][1]benzazepin-6-yl)-N,N-dimethylethane-1,2-diamine
(L
4) of the general formulas [(g
6-p-cymene)M
II(L
1)Cl]Cl,
where M is Ru (4) and Os (6), [(g
6-p-cymene)M
II(L
2)
Cl]Cl, where M is Ru (5) and Os (7), [(g
6-p-cymene)-
M
II(L
3)Cl]Cl, where M is Ru (8) and Os (10), and [(g
6-p-
cymene)M
II(L
4)Cl]Cl, where M is Ru (9) and Os (11), is
reported. The compounds have been comprehensively
characterized by elemental analysis, electrospray ionization
mass spectrometry, spectroscopy (IR, UV–vis, and NMR),
and X-ray crystallography (L
1 HCl, 4 H2O, 5, and
9 2.5H2O). Structure–activity relationships with regard to
cytotoxicity and cell cycle effects in human cancer cells as
well as cyclin-dependent kinase (cdk) inhibition and DNA
intercalation in cell-free settings have been established.
The metal-free indolo[3,2-c]quinolines inhibit cancer cell
growth in vitro, with IC50 values in the high nanomolar
range, whereas those of the related indolo[3,2-d]benzaze-
pines are in the low micromolar range. In cell-free exper-
iments, these classes of compounds inhibit the activity of
cdk2/cyclin E, but the much higher cytotoxicity and
stronger cell cycle effects of indoloquinolines L
1 and 7 are
not paralleled by a substantially higher kinase inhibition
compared with indolobenzazepines L
4 and 11, arguing for
additional targets and molecular effects, such as interca-
lation into DNA.
Keywords Indolo[3,2-d]benzazepines  
Indolo[3,2-c]quinolines   Osmium   Ruthenium
Abbreviations
cdk Cyclin-dependent kinase
DMSO Dimethyl sulfoxide
DTA Differential thermal analysis
ESI Electrospray ionization
GI50 Fifty percent growth inhibition concentration
IC50 Fifty percent inhibitory concentration
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Introduction
The quinolin-2(1H)-one moiety (Structure 1) is involved in
a large number of biologically active compounds [1–8].
Cytotoxic activity of a-methylidene-c-butyrolactones
bearing quinoline, coumarin, ﬂavone, xanthone, and quin-
olin-2(1H)-one heterocycles has been studied, showing that
the latter derivatives were the most potent antiproliferative
agents [8]. Moreover, the indole backbone is a basic
structural component of clinically used anticancer drugs,
e.g., vinblastine [9] and vincristine [10].
Indolo-[3,2-c]quinolines 1a and 1b, combining both
structural units, namely quinolin-2(1H)-one and indole, are
now available [11–13], and further derivatization enables
chemical diversiﬁcation of this class of fused hete-
roaromatics [14–17]. The compounds shown in Structure 2
were tested for cytotoxicity at the US National Cancer
Institute in a panel of about 60 human cancer cell lines. The
results of this screening showed that 1a and 1b exhibit
respectable inhibitory activity, with mean 50% cell growth
inhibition concentrations (GI50) of 19.0 and 18.2 lM,
respectively. Substitution at the lactam unit led to enhanced
cytotoxicity (2a, 4.26 lM vs. 1a, 19.0 lM), which was
further increased by converting the keto function in 2a and
2b into an oxime group, yielding 3a and 3b (GI50 values of
1.70 and 1.35 lM, respectively) [16].
All this indicates that this family of compounds is worth
investigating further as potential antitumor drugs. More-
over, although the library of compounds created is
remarkable, it lacks metal-based derivatives, and the effect
of metal coordination of indolo[3,2-c]quinolines on the
antiproliferative activity and biological mechanisms
involved remained unexplored. This is even more intrigu-
ing when considering that indolo-[3,2-d]benzazepines, also
named paullones (Structure 3), which possess a molecular
structure closely related to indolo[3,2-c]quinolines and
were identiﬁed as cyclin-dependent kinase (cdk) inhibitors
[18], can be readily coordinated to metals by creating
metal-binding sites at the periphery of the molecule skel-
eton able to accommodate metal ions, yielding complexes
with high cytotoxicities and the ability to cause cell cycle
perturbations [19–23]. Recently, a method to convert in-
dolo[3,2-d]benzazepines into the corresponding 6-(car-
boxylic acid)indolo[3,2-c]quinolines was published [24].
In pursuing the goal of developing effective metal-based
antitumor drug candidates and establishing novel struc-
ture–cytotoxicity relationships, we deliberately chose two
related systems for metal coordination, the indolo-[3,2-c]
quinolines L
1 and L
2 and the indolo-[3,2-d]benzazepines
L
3 and L
4 (Structure 4). Compound L
2 was reported to
exhibit high antiproliferative activity in human HL-60
leukemia cells (GI50 of 1.98 lM), alter the cell cycle dis-
tribution via G2/M-phase (in human K562 leukemia cells)
or S-phase arrest (in HL-60 cells), respectively, and induce
apoptosis through the JNK signaling pathway (in K562
cells) [25–27]. We show herein that both indoloquinolines
and indolobenzazepines can be easily attached to ruthe-
nium arene and osmium arene scaffolds, allowing for the
isolation, spectroscopic characterization, and testing for
cytotoxicity of complexes 4–11 (Structure 4) in human
cancer cell lines. The rationale for selection of these two
organic systems for coordination to ruthenium and osmium
was that it might enable (1) elucidation of the effect of
metal coordination on the solubility of the organic com-
pounds L
1–L
4 in aqueous solution and on in vitro anti-
proliferative activity in human cancer cell lines, and (2)
study of the effect of substitution of the folded seven-
membered azepine ring in indolo[3,2-d]benzazepines L
3
and L
4 by a planar six-membered ring in L
1 and L
2 on
solubility, thermal stability, hydrolytic behavior, spectro-
scopic properties, and antiproliferative activity of the cor-
responding metal-based derivatives shown in Structure 4. Structure 1
Structure 2
Structure 3 Kenpaullone and its thiolactam derivative
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123We anticipated that this substitution would enhance
markedly the ability of L
1, L
2, and their metal-based
derivatives to intercalate into DNA, and result in different
cytotoxicity when compared with that of L
3, L
4, and their
metal-containing species. Via the ethane-1,2-diamine
moiety the organic ligands were attached to ruthenium
arene and osmium arene scaffolds, since this provides
different ligand exchange rate kinetics at the metal, another
parameter relevant for the creation of efﬁcient metal-based
antitumor drugs. Ruthenium and osmium arene complexes
with ethane-1,2-diamine-based [28–30] or heteroaromatic
[31–33] ligands are well documented in the literature, and
extensive studies dealing with their biological, physical,
and chemical properties have been published. Interestingly,
the suggested modes of action vary strongly depending on
the ligands and include, e.g., intercalation into DNA [31],
kinase inhibition [33], cell cycle arrest [21], as well as
topoisomerase inhibition [34]. We anticipated that com-
plexation would sustain or enhance the biological activity
of the ligands and alter the pharmacological properties.
Materials and methods
Materials
Ethanol and tetrahydrofuran (THF) were dried using stan-
dard procedures. 7,12-Dihydroindolo[3,2-d][1]benzazepin-
6(5H)-thione was prepared according to a literature pro-
tocol [35]. N0-(11H-Indolo[3,2-c]quinolin-6-yl)-N,N-di-
methylethane-1,2-diamine was synthesized by modiﬁcation
of a reported procedure [25], as described later. N,N-Di-
methylethane-1,2-diamine and ethane-1,2-diamine were
purchased from Fluka/Aldrich and used without further
puriﬁcation. [Ru
IICl(l-Cl)(g
6-p-cymene)]2 [36] and
[Os
IICl(l-Cl)(g
6-p-cymene)]2 [37] were synthesized as
described in the literature. Flavopiridol (Alvocidib) was
kindly provided by Sanoﬁ-Aventis.
Preparation of the ligands and complexes
N-(11H-Indolo[3,2-c]quinolin-6-yl)-ethane-1,2-diamine
(L
1)
A suspension of 6-chloro-11H-indolo[3,2-c]quinoline
(200 mg, 0.79 mmol) and ethane-1,2-diamine (530 lL,
8.00 mmol) in 1-butanol (1.7 mL) was heated at 132 C for
26 h under an argon atmosphere. The reaction mixture was
allowed to cool to room temperature, and the solvent was
removed under reduced pressure. The residue was extrac-
ted with 0.1 M aqueous HCl (6 9 3–4 mL). After ﬁltration
the pH was set to 9–10 by addition of Na2CO3. The product
formed was extracted with ethyl acetate (5 9 30 mL), the
combined organic phases were dried over Na2SO4, ﬁltered,
and the solvent was removed under reduced pressure. The
white product was dried in vacuo. Yield: 186 mg, 85%.
Anal. calcd. for C17H16N4 (Mr 276.33): C, 73.89; H, 5.84;
N, 20.27%. Found: C, 73.63; H, 5.57; N, 20.34%. Solu-
bility in dimethyl sulfoxide (DMSO): 360 mM or greater.
Solubility in 1% DMSO/phosphate-buffered saline (PBS):
275 lM or greater. Single crystals of L
1 HCl suitable for
X-ray diffraction were obtained by slow evaporation of an
ethanolic solution of the raw product.
N0-(11H-Indolo[3,2-c]quinolin-6-yl)-N,N-dimethylethane-
1,2-diamine (L
2)
A suspension of 6-chloro-11H-indolo[3,2-c]quinoline
(423 mg, 1.67 mmol) and N,N-dimethylethane-1,2-di-
amine (440 lL, 4.03 mmol) in 1-butanol (3.5 mL) was
heated at 132 C for 28 h under an argon atmosphere. The
reaction mixture was allowed to cool to room temperature,
and the solvent was removed under reduced pressure. The
residue was dissolved in 0.1 M aqueous HCl (70 mL), and
the pH of the solution was set to 5 by further addition of
0.1 M HCl. After ﬁltration the pH was set to 9–10 by
addition of Na2CO3. The white precipitate formed was
collected, washed with an aqueous solution of Na2CO3, and
dried in vacuo. The raw product was further puriﬁed by
column chromatography, using a 7:1:0.15 CHCl3/CH3OH/
concentrated NH4OH mixture. Yield: 463 mg, 91%. Anal.
Structure 4 Underlining indicates compounds that were character-
ized by X-ray crystallography
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123calcd. for C19H20N4 0.25H2O( Mr 308.89): C, 73.88; H,
6.62; N, 18.14%. Found: C, 73.65; H, 6.33; N, 17.95%.
Solubility in DMSO: 945 mM or greater. Solubility in 1%
DMSO/PBS: 275 lM or greater.
N-(7,12-Dihydroindolo[3,2-d][1]benzazepin-6-yl)-ethane-
1,2-diamine (L
3)
A mixture of 7,12-dihydroindolo[3,2-d][1]benzazepin-
6(5H)-thione (500 mg, 1.89 mmol) and ethane-1,2-diamine
(1.26 mL, 18.90 mmol) in dry THF (30 mL) was reﬂuxed
under light protection and an argon atmosphere for 24 h.
After the mixture had been cooled to room temperature, it
was ﬁltered, the solvent was evaporated to dryness, and the
oily residue was suspended in water to yield a white pre-
cipitate. The latter was ﬁltered off and dissolved in diethyl
ether (80 mL). Half of the solvent was removed under
reduced pressure,and the remainingsolution was allowed to
stand at -20 C for crystallization. After 3 days the pre-
cipitate was collected under suction, washed with a small
amount of cold diethyl ether (5 mL), and dried in vacuo.
Yield: 272 mg, 50%. Anal. calcd. for C18H18N4 0.4H2O( Mr
297.57): C, 72.65; H, 6.37; N, 18.83%. Found: C, 72.88; H,
6.01; N, 18.40%. Solubility in DMSO: 197 mM or greater.
Solubility in 1% DMSO/PBS: 225 lM or greater.
N0-(7,12-Dihydroindolo[3,2-d][1]benzazepin-6-yl)-N,N-
dimethylethane-1,2-diamine (L
4)
A mixture of 7,12-dihydroindolo[3,2-d][1]benzazepin-
6(5H)-thione (2.00 g, 7.57 mmol) and N,N-dimethyl-
ethane-1,2-diamine (1.50 mL, 13.73 mmol) in dry THF
(120 mL) was reﬂuxed at 80 C for 26 h under an argon
atmosphere. After ﬁltration the solvent was evaporated to
dryness. The residue was suspended in hexane (10 mL),
ﬁltered off, and dissolved in diethyl ether (150 mL). About
half of the solvent was removed under reducedpressure, and
the remaining solution was allowed to stand at -20 C for
crystallization. After 3 days the precipitate was ﬁltered off,
washed with cold diethyl ether, and dried in vacuo. Yield:
1.74 g, 72%. Anal. calcd. for C20H22N4 0.20H2O
(Mr 322.02):C,74.60;H,7.01;N,17.40%.Found:C,74.58;
H, 6.75; N, 17.13%. Solubility in DMSO: 885 mM or
greater. Solubility in 1% DMSO/PBS: 380 lM or greater.
[(g
6-p-Cymene)Ru
II(L
1)Cl]Cl, (g
6-p-cymene)
(jN-[11H-indolo[3,2-c]quinolin-6-ylidene]-jN0-ethane-1,
2-diamine)chloridoruthenium(II) chloride (4)
A mixture of [Ru
IICl(l-Cl)(g
6-p-cymene)]2 (111 mg,
0.18 mmol) and L
1 (100 mg, 0.36 mmol) in dry ethanol
(2.5 mL) was stirred under an argon atmosphere for 24 h.
The orange precipitate was ﬁltered off, washed with cold
ethanol (1.5 mL), and dried in vacuo. Yield: 193 mg, 91%.
Anal. calcd. for C27H30N4Cl2Ru H2O( Mr 600.54): C,
54.00; H, 5.37; N, 9.33%. Found: C, 53.78; H, 5.29; N,
9.05%. Solubility in DMSO: 228 mM or greater. X-ray
diffraction quality crystals were obtained by slow evapo-
ration of a solution of 4 in 1:3 methanol/diethyl ether.
[(g
6-p-Cymene)Ru
II(L
2)Cl]Cl, (g
6-p-cymene)(jN0-[11H-
indolo[3,2-c]quinolin-6-ylidene]-jN,N-dimethylethane-
1,2-diamine)chloridoruthenium(II) chloride (5)
A mixture of [Ru
IICl(l-Cl)(g
6-p-cymene)]2 (101 mg,
0.16 mmol) and L
2 (100 mg, 0.33 mmol) in dry ethanol
(2.3 mL) was stirred under an argon atmosphere at room
temperature for 23 h. The orange precipitate formed was
ﬁltered off, washed with ethanol (1.5 mL), and dried in
vacuo for 48 h. Yield: 141 mg, 70%. Anal. calcd. for
C29H34N4Cl2Ru (Mr 610.58): C, 57.04; H, 5.61, N, 9.18%.
Found: C, 57.13; H, 5.41; N, 9.18%. Solubility in DMSO:
21 mM or greater. Solubility in 1% DMSO/PBS: 210 lM
or greater. Single crystals suitable for X-ray diffraction
study were obtained by slow diffusion of diethyl ether into
the solution of the complex in ethanol.
[(g
6-p-Cymene)Os
II(L
1)Cl]Cl, (g
6-p-cymene)(jN-[11H-
indolo[3,2-c]quinolin-6-ylidene]-jN0-ethane-1,2-diamine)
chloridoosmium(II) chloride (6)
A mixture of [Os
IICl(l-Cl))(g
6-p-cymene)]2 (87 mg,
0.11 mmol) and L
1 (61 mg, 0.22 mmol) in dry ethanol
(1.8 mL) was stirred under light protection and an argon
atmosphere at room temperature for 23 h. The yellow
precipitate formed was ﬁltered off, washed with cold
ethanol (1.5 mL), and dried in vacuo. Yield: 100 mg, 68%.
Anal. calcd. for C27H30N4Cl2Os 0.5H2O( Mr 680.70): C,
47.64; H, 4.59; N, 8.32%. Found: C, 47.87; H, 4.55; N,
8.31%. Solubility in DMSO: 235 mM or greater. Solubility
in 1% DMSO/PBS: 260 lM or greater.
[(g
6-p-Cymene)Os
II(L
2)Cl]Cl, (g
6-p-cymene)(jN0-[11H-
indolo[3,2-c]quinolin-6-ylidene]-jN,N-dimethylethane-
1,2-diamine)chloridoosmium(II) chloride (7)
A mixture of [Os
IICl(l-Cl)(g
6-p-cymene)]2 (130 mg,
0.16 mmol) and L
2 (100 mg, 0.33 mmol) in dry ethanol
(2.3 mL) was stirred under light protection and an argon
atmosphere at room temperature for 23 h. The yellow
precipitate formed was ﬁltered off, washed with ethanol
(0.5 mL), and dried in vacuo. Yield: 147 mg, 64%. Anal.
calcd. for C29H34N4Cl2Os 0.5H2O( Mr 708.75): C, 49.14;
H, 4.98; N, 7.91%. Found: C, 49.03; H, 4.70; N, 7.74%.
Solubility in DMSO: 23 mM or greater. Solubility in
1% DMSO/PBS: 230 lM or greater.
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123[(g
6-p-Cymene)Ru
II(L
3)Cl]Cl, (g
6-p-cymene)(jN-[7,12-
dihydroindolo[3,2-d][1]benzazepin-6-ylidene]-jN0-ethane-
1,2-diamine)chloridoruthenium(II) chloride (8)
A mixture of [Ru
IICl(l-Cl)(g
6-p-cymene)]2 (127 mg,
0.21 mmol) and L
3 (120 mg, 0.41 mmol) in dry ethanol
(4 mL) was stirred under an argon atmosphere at 50 C for
4 h. After the reaction mixture had been cooled to room
temperature, the product was precipitated by addition of
diethyl ether (25 mL), ﬁltered off, washed with diethyl
ether (2 9 5 mL), and dried at 60 C in vacuo. Yield:
193 mg, 78%. Anal. calcd. for C28H32N4Cl2Ru 1.25H2O
(Mr 619.08): C, 54.32; H, 5.62; N, 9.05%. Found:
C, 54.30; H, 5.31; N, 8.93%. Solubility in DMSO:
246 mM or greater. Solubility in 1% DMSO/PBS: 315 lM
or greater.
[(g
6-p-Cymene)Ru
II(L
4)Cl]Cl, (g
6-p-cymene)(jN0-[7,12-
dihydroindolo[3,2-d][1]benzazepin-6-ylidene]-jN,N-
dimethylethane-1,2-diamine)chloridoruthenium(II)
chloride (9)
A mixture of L
4 (50 mg, 0.16 mmol) and [Ru
IICl(l-Cl)(g
6-
p-cymene)]2 (48 mg, 0.08 mmol) in dry ethanol (2.3 mL)
was stirred under an argon atmosphere at 50 C for 4.4 h.
After cooling to room temperature, by slow diffusion of
diethyl ether into the red-brown solution the orange
product crystallized. The crystals were separated and
dried in vacuo. Yield: 90 mg, 92%. Anal. calcd. for
C30H36N4Cl2Ru H2O( Mr 642.60): C, 56.07; H 5.96;
N, 8.72%. Found: C, 56.21; H, 6.02; N, 8.56%. Solubility
in DMSO: 189 mM or greater. Solubility in 1% DMSO/
PBS: 465 lM or greater. Crystals suitable for X-ray dif-
fraction study were obtained by slow diffusion of diethyl
ether into the reaction mixture.
[(g
6-p-Cymene)Os
II(L
3)Cl]Cl, (g
6-p-cymene)(jN-[7,12-
dihydroindolo[3,2-d][1]benzazepin-6-ylidene]-jN0-ethane-
1,2-diamine)chloridoosmium(II) chloride (10)
A mixture of [Os
IICl(l-Cl)(g
6-p-cymene)]2 (137 mg,
0.17 mmol) and L
3 (100 mg, 0.35 mmol) in dry ethanol
(4 mL) was stirred under an argon atmosphere at 50 C for
4 h. After the reaction mixture had been cooled to room
temperature, the product was precipitated by addition of
diethyl ether (25 mL), ﬁltered off, washed with diethyl
ether (3 9 5 mL), and dried at 60 C in vacuo. Yield:
159 mg, 67%. Anal. calcd. for C28H32N4Cl2Os H2O
(Mr 703.73): C, 47.79; H, 4.87; N, 7.96%. Found:
C, 47.86; H, 4.58; N, 8.02%. Solubility in DMSO:
235 mM or greater. Solubility in 1% DMSO/PBS: 110 lM
or greater.
[(g
6-p-Cymene)Os
II(L
4)Cl]Cl, (g
6-p-cymene)(jN0-[7,
12-dihydroindolo[3,2-d][1]benzazepin-6-ylidene]-jN,N-
dimethylethane-1,2-diamine)chloridooosmium(II)
chloride (11)
A mixture of [Os
IICl(l-Cl)(g
6-p-cymene)]2 (124 mg,
0.157 mmol) and L
4 (100 mg, 0.31 mmol) in dry ethanol
(4 mL) was stirred under light protection and an inert
atmosphere at 50 C for 4 h. After the solution had been
cooled to room temperature, diethyl ether (20 mL) was
added to precipitate the product. The yellow powder was
collected by ﬁltration, washed with diethyl ether
(2 9 8 mL), and dried in vacuo at 60 C. Yield:182 mg,
81%. Anal. calcd. for C30H36N4Cl2Os H2O( Mr 731.78):
C, 49.24; H, 5.23; N, 7.66. Found: C, 49.02; H, 5.23;
N, 7.52%. Solubility in DMSO: 167 mM or greater. Sol-
ubility in 1% DMSO/PBS: 460 lM or greater. Single
crystals of X-ray diffraction quality were grown by slow
diffusion of diethyl ether into an ethanolic solution of the
complex. The complex was found to be isostructural with
its ruthenium analogue 9, crystallizing in the monoclinic
space group P21/n with the following cell parameters: a =
12.9857(11) A ˚, b = 19.2791(17) A ˚, c = 13.2419(10) A ˚,
and b = 109.589(5).
Physical measurements
One-dimensional
1H and
13C NMR and two-dimensional
1H–
1H correlation spectroscopy,
1H–
1H total correlation
spectroscopy,
1H–
1H rotating frame Overhauser enhance-
ment spectroscopy or
1H–
1H nuclear Overhauser enhance-
ment spectroscopy,
1H–
13C heteronuclear single quantum
coherence, and
1H–
13C heteronuclear multiple bond corre-
lation NMR spectra were recorded using two Bruker
Avance III spectrometers at 500.32 or 500.10 MHz (
1H)
and 125.82 or 125.76 (
13C) MHz, respectively, by using as
a solvent DMSO-d6 or MeOD-d4 at room temperature and
standard pulse programs.
1H and
13C shifts are quoted rel-
ative to the solvent residual signals. The atom numbering
used for assignments is depicted in Scheme S3. IR spectra
were measured with a Bruker Vertex 70 Fourier transform
IR spectrometer by means of the attenuated total reﬂection
technique, and UV–vis spectra were recorded with a Perk-
inElmer Lambda 650 spectrophotometer. Shoulders were
evaluated by using the ﬁrst derivatives of the spectra.
Electrospray ionization (ESI) mass spectrometry was car-
ried out with a Bruker Esquire 3000 instrument; the samples
were dissolved in methanol. Thermogravimetric analysis
(TGA) and differential thermal analysis (DTA) were carried
out with a Mettler Toledo TGA/SDTA 851
e instrument.
The substances were ﬂushed with nitrogen (50 mL/min) at
25 C for 30 min and then heated to 700 C in a nitrogen
stream (50 mL/min), with a heating rate of 5 C/min. All
J Biol Inorg Chem (2010) 15:903–918 907
123elemental analyses were performed at the Microanalytical
Laboratory of the University of Vienna with a PerkinElmer
2400 CHN elemental analyzer.
Crystallographic structure determination
X-ray diffraction measurements were performed using a
Bruker X8 APEXII CCD diffractometer. Single crystals
were positioned at 35, 35, 40, and 40 mm from the
detector, and 1,066, 2,768, 1,705, and 1,451 frames were
measured, each for 120, 20, 80, and 40 s over 1 scan width
for L
1 HCl, 4 H2O, 5, and 9 2.5H2O, respectively. The data
were processed using SAINT Plus [38]. Crystal data, data
collection parameters, and structure reﬁnement details are
given in Table 1. The structures were solved by direct
methods and reﬁned by full-matrix least-squares tech-
niques. Non-hydrogen atoms were reﬁned with anisotropic
displacement parameters. Hydrogen atoms were inserted in
calculated positions and reﬁned with a riding model. The
following software programs, computer, and tables were
used: SHELXS-97 for structure solution [39]; SHELXL-97
for reﬁnement [40]; ORTEP for molecular diagrams [41]; a
Pentium IV computer; Tables 4.2.6.8 and 6.1.1.4 in [42]
for scattering factors.
Cell lines and culture conditions
CH1 (ovarian carcinoma, human) cells were donated by
Lloyd R. Kelland (CRC Centre for Cancer Therapeutics,
Institute of Cancer Research, Sutton, UK). SW480 (colon
adenocarcinoma, human) cells and A549 (non-small cell
lung cancer, human) cells were kindly provided by Brigitte
Marian (Institute of Cancer Research, Department of
Medicine I, Medical University of Vienna, Austria). Cells
were grown without antibiotics in 75-cm
2 culture ﬂasks
(Iwaki/Asahi Technoglass) as adherent monolayer cultures
in minimal essential medium supplemented with 10% heat-
inactivated fetal bovine serum, 1 mM sodium pyruvate,
and 2 mM L-glutamine (all purchased from Sigma–
Aldrich). Cultures were maintained at 37 C in a humidi-
ﬁed atmosphere containing 5% CO2 and 95% air.
Cytotoxicity in cancer cell lines
Cytotoxicity in the cell lines mentioned in the previous
section was determined by the colorimetric 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT;
purchased from Sigma–Aldrich) assay. For this purpose,
cells were harvested from culture ﬂasks by trypsinization
Table 1 Crystal data and details of data collection for L
1 HCl, 4 H2O, 5, and 9 2.5H2O
L
1 HCl 4 H2O 59  2.5H2O
Empirical formula C17H17ClN4 C27H32Cl2N4ORu C29H34Cl2N4Ru C30H41Cl2N4O2.5Ru
Formula weight 312.80 600.54 610.57 669.65
Space group Pnma P21/cP 21/nP 21/n
a (A ˚) 19.552(2) 11.2077(4) 10.7821(6) 12.9729(7)
b (A ˚) 6.5845(12) 15.5943(5) 20.7288(12) 19.1797(11)
c (A ˚) 11.6690(18) 15.5918(5) 12.0944(7) 13.1560(6)
b () 103.277(2) 93.834(4) 109.911(3)
V (A ˚ 3) 1,502.3(4) 2,652.24(15) 2,697.0(3) 3,077.8(3)
Z 4444
k (A ˚) 0.71073 0.71073 0.71073 0.71073
qcalcd (g cm
-3) 1.383 1.504 1.504 1.445
Crystal size (mm
3) 0.20 9 0.04 9 0.04 0.20 9 0.20 9 0.15 0.13 9 0.10 9 0.03 0.12 9 0.12 9 0.10
T (K) 100 100 296 100
l (mm
-1) 0.256 0.820 0.805 0.718
R1
a 0.0894 0.0279 0.0425 0.0414
wR2
b 0.2049 0.0652 0.0965 0.0993
GOF
c 1.015 1.014 0.956 1.031
GOF goodness of ﬁt
a R1 = R||Fo| - |Fc||/R|Fo|.
b wR2 = {R[w(Fo
2 - Fc
2)
2]/R[w(Fo
2)
2]}
1/2
c GOF = {R[w(Fo
2 - Fc
2)
2]/(n - p)}
1/2, where n is the number of reﬂections and p is the total number of parameters reﬁned
908 J Biol Inorg Chem (2010) 15:903–918
123and seeded in 100-lL aliquots in minimal essential med-
ium supplemented with 10% heat-inactivated fetal bovine
serum, 1 mM sodium pyruvate, 4 mM L-glutamine, and 1%
nonessential amino acids (1009) (all purchased from
Sigma–Aldrich) into 96-well microculture plates (Iwaki/
Asahi Technoglass). The following cell densities were
chosen, to ensure exponential growth of untreated controls
throughout the experiment: 1.5 9 10
3 (CH1), 2.5 9 10
3
(SW480), and 4.0 9 10
3 (A549) viable cells per well. For
24 h, cells were allowed to settle and resume exponential
growth, followed by the addition of dilutions of the test
compounds in aliquots of 100 lL per well in the same
medium. After continuous exposure for 96 h, the medium
was replaced by 100 lL RPMI 1640 medium (supple-
mented with 10% heat-inactivated fetal bovine serum and
4m ML-glutamine) per well plus a 20 lL per well solution
of MTT in PBS (5 mg/mL) (all purchased from Sigma–
Aldrich). After incubation for 4 h, medium/MTT mixtures
were removed, and the formazan product formed by viable
cells was dissolved in DMSO (150 lL per well). Optical
densities at 550 nm were measured with a microplate
reader (Tecan Spectra Classic), using a reference wave-
length of 690 nm to correct for unspeciﬁc absorption. The
quantity of viable cells was expressed as the percentage of
untreated controls, and 50% inhibitory concentrations
(IC50) were calculated from concentration–effect curves by
interpolation. Evaluation was based on at least three
independent experiments, each comprising three replicates
per concentration.
DNA intercalation
The capacity of the test compounds to intercalate into
salmon sperm DNA was determined by the methyl green
assay [43] with minor modiﬁcations as described previ-
ously [44]. Brieﬂy, salmon sperm DNA (10 mg/mL) was
incubated for 1 h at 37 C with 32 lM methyl green.
Reduction of the absorbance of methyl green at 642 nm
induced by the test compounds after incubation for 2 h at
37 C was measured with a ﬂuorescence reader (Bio-Tek
Synergy HT).
Kinase assay
The activities of recombinant cdk1/cyclin B and cdk2/
cyclin E expressed in and isolated from Sf21 insect cells
were determined by a modiﬁed radioassay [45], using
histone H1 as the substrate for phosphorylation. Brieﬂy,
assay mixtures containing the test compound (except for
untreated controls), the respective kinase/cyclin complex,
histone H1, and 0.4 lCi (c-
32P)ATP per sample were
incubated for 10 min at 30 C. Aliquots of the solution
were spotted onto phosphocellulose squares, which had
been washed three times with 0.75% phosphoric acid fol-
lowed by acetone. The dried squares were measured in
scintillation vials by b-counting (PerkinElmer Tri-Carb
2800TR; software program Quanta Smart). Results were
obtained in duplicates in at least two independent experi-
ments, and IC50 values were calculated by interpolation.
Cell cycle analyses
One million A549 cells were seeded into Petri dishes and
allowed to recover for 24 h. Cells were then exposed for
24 h to the test compounds. Control and treated cells were
collected, washed with PBS, ﬁxed in 70% ice-cold ethanol,
and stored at -20 C. To determine cell cycle distribu-
tions, cells were transferred in physiological NaCl solution
into PBS, incubated with 10 lg/mL RNase A for 30 min at
37 C, followed by treatment with 5 lg/mL propidium
iodide for 30 min, and their ﬂuorescence was measured by
ﬂow cytometry, using a FACSCalibur instrument (Becton
Dickinson, Palo Alto, CA, USA). The resulting DNA his-
tograms were quantiﬁed by Cell Quest Pro (Becton Dick-
inson, New York, NY, USA).
Results and discussion
Synthesis and characterization of ligands and metal
complexes
Compound L
1 was prepared by reaction of 6-chloro-11H-
indolo[3,2-c]quinoline with 10 equiv of ethane-1,2-diamine
in 1-butanol at 132 C for 26 h under an argon atmosphere
in 85% yield. A large excess of ethane-1,2-diamine was
used to avoid formation of a 2:1 condensation product of
6-chloro-11H-indolo[3,2-c]quinoline with ethane-1,2-di-
amine (Scheme S1). The synthesis of L
2 was realized in a
similar way by using a twofold excess of N,N-dimethyl-
ethane-1,2-diamine in 91% yield (Scheme S1). It should,
however, be noted that the synthesis of L
2 is well docu-
mented in the literature [25]. Compounds L
3 and L
4 were
synthesized by reacting thiolactam 7,12-dihydroindolo[3,2-d]-
[1]benzazepin-6(5H)-thione [35] with 10 equiv of ethane-1,2-
diamine and 1.9 equiv of N,N-dimethylethane-1,2-diamine,
respectively, in dry THF at 80 C for 26 h under an argon
atmosphere (Scheme S2).
Ruthenium(II) and osmium(II) complexes 4–11 were
prepared in 64–91% yield by following a conventional
protocol of a bridge splitting reaction of dimeric starting
material [(g
6-p-cymene)M
II(l-Cl)Cl]2 (M is Ru, Os) with
ligands L
1–L
4 in dry ethanol.
The positive ion ESI mass spectra of L
1–L
4 show the
presence of peaks at m/z 277, 305, 291, and 319, attributable
to [L
1 ? H]
?,[ L
2 ? H]
?,[ L
3 ? H]
?, and [L
4 ? H]
?,
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123respectively. In addition, peaks at m/z 327 and 260 for L
2
and m/z 341 and 274 for L
4 were assigned to [M ? Na]
?
and [M–N(CH3)2]
?, where M is the molecular ion,
respectively. For 4 and 6, the complex cations [(g
6-p-
cymene)Ru
II(L
1)Cl]
? and [(g
6-p-cymene)Os
II(L
1)Cl]
?
display moderate peaks at m/z 547 and 637, respectively.
However, the strongest are the signals at m/z 511 and 601,
attributed to [(g
6-p-cymene)M
II(L
1)-HCl]
?, where
M
II is Ru
II and Os
II. A peak of low relative intensity at m/z
277 in 4 is due to [L
1 ? H]
?. Strong peaks at m/z 539 and
629 in the mass spectra of 5 and 7 were attributed to [(g
6-p-
cymene)M
II(L
2)-HCl]
?, where M
II is Ru
II and Os
II,
whereas those at m/z 494 and 585 were attributed to a
fragment ion [(g
6-p-cymene)M
II{L
2-HN(CH3)2}]
?, where
M
II is Ru
II and Os
II. The same type of fragment ions,
namely, [(g
6-p-cymene)M
II{L
4-HN(CH3)2}]
?, were also
observed for 9 and 11, but they were clearly less abundant.
Peaks at m/z 561, 589, 651, and 679 in the mass spectra of
8–11 were assigned to [(g
6-p-cymene)M
II(L
3)Cl]
? and [(g
6-
p-cymene)M
II(L
4)Cl]
? (M
II is Ru
II,O s
II), whereas those at
m/z 525 and 613 and at m/z 553 and 641 were assigned to
[(g
6-p-cymene)M
II(L
3)-HCl]
? and [(g
6-p-cymene)-
M
II(L
4)-HCl]
? (M
II is Ru
II,O s
II), respectively.
Both the organic compounds and the metal complexes
are soluble in DMSO. By complexation, solubility is sig-
niﬁcantly altered. Whereas the solubility of the ligands in
DMSO is about 2.6 times (L
1, 360 mM; L
2, 945 mM) to
4.5 times (L
3, 197 mM; L
4, 885 mM) higher for the
dimethylated species, this ratio is reversed for the com-
plexes. This effect is quite strong in the case of the indo-
loquinolines, where the solubility of the dimethylated
complexes is about one tenth that of the ethane-1,2-di-
amine species (4, 227 mM; 5, 21 mM; 6, 235 mM; 7,
23 mM), but is less pronounced for the indolo[3,2-d]benz-
azepine derivatives by factors of 1.3 (8, 245 mM; 9,
189 mM) to 1.4 (10, 235 mM; 11, 167 mM). Whereas
solubility is about the same for the indoloquinoline- and
indolobenzazepine-based ethylenediamine complexes,
there are large differences in the case of the dimethylated
species, which differ by factors of 9.0 (9 vs. 5) and 7.3 (11
vs. 7), respectively. The difference in solubility between
osmium and ruthenium compounds is negligible. The sol-
ubility in 1% DMSO/PBS was also evaluated. The solu-
bility of 4 could not be determined, as ligand exchange was
so fast that a white precipitate was formed nearly instan-
taneously after dilution of the DMSO stock solution with
PBS. The other indoloquinoline-based complexes (5–7) are
more stable and show quite similar solubility: 210 lM( 5)
and 260 lM( 6). The difference between the comparable
ruthenium and osmium compounds (5 and 7) is also neg-
ligible. For the indolobenzazepine compounds the situation
is different. Whereas the solubility of ruthenium species 8
is markedly higher than that of its osmium congener 10
(315 vs. 110 lM), dimethylated ruthenium and osmium
complexes 9 and 11 exhibit the same solubility of about
460 lM. Notably, this is the highest solubility of all the
complexes studied. Dimethylated indolobenzazepine spe-
cies 9 and 11 exhibit solubility twice as high as the com-
parable indoloquinoline complexes 5 and 7, where the
solubility in 1% DMSO/PBS is limited by the fairly low
solubility in DMSO. Compared with the corresponding
ligands, the indoloquinoline-based complexes are slightly
less soluble, whereas the indolobenzazepine-based com-
plexes show higher solubility.
The NMR spectra of the racemic complexes show the
typical pattern of a molecule with diastereotopic splitting
of protons neighboring the chiral metal center. Therefore,
four distinct signals for the p-cymene protons and two
signals for each CH2 group of the ethanediamine moiety
can be found. The relative position of the cymene protons
cy1/cy2/cy4 and cy10/cy20/cy40 was assigned using the two-
dimensional spectra; the position relative to ligands L
1–L
4
could not be elucidated.
In the case of 4, recording of a
13C NMR spectrum and
assignment of the resonances was not possible owing to its
instability both in DMSO and in methanol. After 24 h in
DMSO-d6 complex 4 displayed an NMR spectrum identi-
cal with that of the metal-free ligand.
The thermal properties of all complexes were studied by
TGA between 25 and 700 C under a nitrogen atmosphere
(Fig. S4). The TGA curves of 5, 7, and 8 indicate that they
are nonsolvated. Complexes 4, 6, and 9–11 are solvated
species. Desolvation occurs in two consecutive steps (4, 6,
and 9) or in a single step (10 and 11) between 35 and 180 C
and is accompanied by endothermic peaks in the corre-
sponding DTA curves scanned simultaneously. Endother-
mic peaks at approximately 220 C for 6 and 11 are
presumably due to melting, which is followed by decom-
position. The thermally most stable is 10, with decomposi-
tion starting at approximately 250 C. All other compounds
have starting decomposition temperatures between 200 and
230 C, indicating that the thermal stability of both ruthe-
nium(II) and osmium(II) complexes with both indolo[3,2-
c]quinolines and indolo[3,2-d]benzazepines is quite similar.
The UV–vis spectra of the methanolic solutions of the
ligands are depicted in Fig. S1. Whereas indolo[3,2-
d]benzazepine derivatives L
3 and L
4 show the strongest
absorption at about 230 nm, the indolo[3,2-c]quinolines L
1
and L
2 exhibit a bathochromic shift with absorption max-
ima at approximately 265 nm. These differences can be
explained by the conjugated systems of the indoloquinoline
derivatives. The stability of the complexes in methanol
(Fig. S2) and 0.5% DMSO/PBS (Fig. S3) was monitored
by UV–vis spectroscopy. In both media indolobenz-
azepine-based complexes 8–11 are kinetically more inert
toward ligand exchange reactions than the metal-based
910 J Biol Inorg Chem (2010) 15:903–918
123indolo[3,2-c]quinolines. In methanol, the UV–vis as well
as the ESI mass spectra remained unchanged for 24 h, and
in aqueous media only a slight decrease in absorption was
observed. The indoloquinoline-based complexes seem to
undergo ligand exchange reactions, both in methanol and in
aqueous media. The ESI mass spectra of indoloquinoline
complexes 4–7 in methanol were measured immediately
after dissolution (vide supra) and after 24 h. For 4 and 5 a
new peak with m/z 565 was observed after 24 h, which was
attributed to the dimer [{(g
6-p-cymene)Ru}2(l-OCH3)3]
?.
Similarly, the presence of a peak with m/z 743 in the mass
spectrum of 7 was assigned to [{(g
6-p-cymene)Os}2(l-
OCH3)3]
?. It should be noted that the experimental isotopic
patterns agreed well with those calculated. In addition
peaks with m/z 206 and 305 indicate the presence of the
metal-free ligands in methanolic solutions after 24 h in the
case of 5 and 7. Complex 6 remained intact in methanol
over 24 h, revealing a peak with m/z 601 attributed to
[(g
6-p-cymene)Os
II(L
1)-HCl]
?.
Crystal structures
The results of the X-ray diffraction studies of the metal-
free indolo[3,2-c]quinoline L
1 as a hydrochloride salt, [(g
6-
p-cymene)Ru(L
1)Cl]Cl H2O( 4 H2O), [(g
6-p-cymene)Ru
(L
2)Cl]Cl (5), and [(g
6-p-cymene)Ru(L
4)Cl]Cl 2.5H2O( 9)
are shown in Figs. 1, 2, 3, and 4, respectively.
The hydrochloride salt of L
1 crystallized in the ortho-
rhombic space group Pnma. The indolo[3,2-c]quinoline is
protonated at the terminal nitrogen atom of the ethylene-
diamine moiety, as evidenced by hydrogen-bonding inter-
actions between the disordered nitrogen atoms and the
chloride counterion. The donor–acceptor separation is
2.917 A ˚ for both disordered nitrogen atoms N4   Cl and
N4x   Cl
i(x, y ? 1, z). The indolo[3,2-c]quinoline skeleton
lies on a crystallographic mirror plane and is therefore
Fig. 1 Structure of the protonated ligand in L
1 HCl, showing the
disorder in the ethylenediamine moiety
Fig. 2 Structure of the complex cation in 4 H2O with thermal
ellipsoids drawn at the 50% probability level
Fig. 3 Fragment of the crystal structure of 5 with thermal ellipsoids
drawn at the 30% probability level with one intramolecular hydrogen
bond N2–H   Cl1 and one intermolecular hydrogen bond N1–H   Cl2
i
Fig. 4 Projection of the structure of the complex cation in 9 2.5H2O
with thermal ellipsoids drawn at the 50% probability level with an
intramolecular hydrogen-bonding interaction N2–H   Cl1
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123perfectly planar. The distribution of the electron density
over the fragment N2–C12–N3 [N2–C12 1.339(9) A ˚, C12–
N3 1.352(8) A ˚] indicates the prevalence of the tautomeric
form with the endocyclic amidine C=N bond.
All complexes have the characteristic ‘‘three-leg piano-
stool’’ geometry of ruthenium(II) arene complexes [28, 46–
49], with an g
6 p-bound p-cymene ring forming the seat and
three other donor atoms (of one bidentate indolo[3,2-
c]quinoline or indolo[3,2-d]benzazepine ligand and one
chlorido ligand) as the legs of the stool. Selected bond
distances and angles are given in Table 2. The complexes
are racemates owing to the presence of the stereogenic
metal center. Complexes 4 H2O and 5 are the ﬁrst metal-
based indolo[3,2-c]quinolines characterized crystallo-
graphically. The indolo[3,2-c]quinoline ligands in 4 and 5
adopt tautomeric forms different from that found in the
metal-free compound L
1 HCl, with an exocyclic amidine
double bond, as can be clearly seen from the distribution
of the electron density over the fragments N2–C12–N3
[N2–C12 1.379(2) and 1.377(5) A ˚, C12–N3 1.315(2) and
1.331(5) A ˚, for 4 H2O and 5, respectively]. Upon binding to
ruthenium(II), the ligands form a ﬁve-membered metallo-
cycle N3C13C14N4Ru. The torsion angle HN3–C13–C14–N4,
which serves as a measure of the deviation of the chelate
ring from planarity, is 56.12(19) and 58.7(4) in 4 H2O and
5, respectively.
A hydrogen bond between indole nitrogen N1 as a proton
donor and the chloride counterion Cl2
i (symmetry code i:
-x ? , y ? , -z ? ) as a proton acceptor (Fig. 3)i s
also evident in the crystal structure of 5 [N1–H 0.86 A ˚,
H   Cl2
i 2.270 A ˚,N 1    Cl2 3.075 A ˚, N1HCl2
i 155.94].
A salient feature in the structure of 9 2.5H2O is the
folded conformation of the indolobenzazepine ligand L
4
bound to ruthenium. In contrast to the essentially planar
indolo[3,2-c]quinoline backbone (see Fig. 1), the indolo-
[3,2-d]benzazepine main skeleton contains one sp
3-
hybridized carbon atom, i.e., the methylene group of the
seven-membered azepine ring. This atom interrupts the
conjugation of the p system, and the ligand as a whole is
nonplanar. The dihedral angle between the phenyl and
indole rings can be characterized by a torsion angle
of HN1–C5–C6–C7, which is -33.5(6) compared with
-36.84(18) in the metal-free 9-bromo-indolo[3,2-d]-
benzazepine [50]. L
3 and L
4 act as neutral ligands and are
stabilized in a different tautomeric form compared with
that in the metal-free derivative brominated at position 9.
The hydrogen atom is attached to N2, and the N2–C12
bond length of 1.357(6) A ˚ is signiﬁcantly longer than C12–
N3 of 1.302(5) A ˚, the latter possessing a pronounced
double-bond character. Intramolecular hydrogen bonding
between N2 and Cl1 [N2–H 0.880, H   Cl1 2.722 A ˚,
N2   Cl1 3.429 A ˚, N2–H   Cl1 138.22] stabilizes the
ligand in E conﬁguration with the exocyclic double C=N
bond. Upon binding to ruthenium(II), the ligand forms a
ﬁve-membered N3C13C14N4Ru metallocycle. The torsion
angle HN3–C13–C14–N4 is 54.9(5) in 9 2.5H2O.
Cytotoxicity in cancer cell lines
The cytotoxicity of compounds L
2, L
4, and 5–11 was
assessed by means of a colorimetric microculture assay
(MTT assay) in three human cancer cell lines, namely, CH1
(ovarian carcinoma), SW480 (colon adenocarcinoma), and
A549 (non-small-cell lung carcinoma). The sensitivities of
these cell lines show mostly small differences, but the
generally more chemoresistant non-small-cell lung cancer
cell line A549 is also the least sensitive throughout this
series of compounds. The generally more chemosensitive
ovarian cancer cell line CH1 is the most sensitive only to
indolobenzazepine derivatives L
4 and 8–11, whereas in-
doloquinoline derivatives L
2 and 5–7 are most cytotoxic to
the colon cancer cell line SW480. The calculated IC50
values are listed in Table 3, and the corresponding con-
centration–effect curves are depicted in Figs. 5, 6, and 7,
illustrating the following structure–activity relationships:
the high cytotoxic potency of indoloquinoline derivative L
2
could only be slightly (if at all) increased by complexation,
with hardly a difference between ruthenium and osmium
(up to 1.8 times in the case of ruthenium complex 5 and up
to 1.6 times in the case of osmium complex 7, based on a
Table 2 Selected bond distances (angstroms) and angles (degrees) for complexes 4 H2O, 5, and 9 2.5H2O
4 H2O 59  2.5H2O
Ru–N3 2.1174(15) 2.105(3) 2.122(3)
Ru–N4 2.1257(15) 2.204(3) 2.177(3)
Ru–Cl1 2.4208(5) 2.4229(11) 2.4168(11)
Ru–C(18–23)av/Ru–C(20–25)av/Ru–C(21–26)av 2.186(14) 2.191(24) 2.197(8)
C–C(18–23)av/C–C(20–25)av/C–C(21–26)av 1.416(14) 1.404(20) 1.412(17)
N3–Ru–N4 79.26(6) 80.45(12) 79.44(14)
N3–Ru–Cl1 88.79(4) 87.15(9) 85.01(10)
N4–Ru–Cl1 85.12(4) 88.27(10) 88.41(10)
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123comparison of IC50 values), which might result from
insufﬁcient stability in the cell culture medium. In any case,
there are no clear-cut synergistic effects of metal and
ligand. The cytotoxicity of complex 6 differs only slightly
from that of analogue 7, showing that terminal dimethyla-
tion of the ethane-1,2-diamine side chain has little conse-
quence for biological activity (Fig. 5).
In contrast, the cytotoxic potency of indolobenzazepine
derivative L
4 could be markedly enhanced by complexa-
tion, but again with little difference between ruthenium and
osmium. This enhancement amounts to 6.8–16-fold,
depending on the cell line, in the case of ruthenium complex
9 and ﬁvefold to tenfold in the case of osmium complex 11.
The terminally dimethylated ethane-1,2-diamine side chain
is slightly favorable in terms of cytotoxicity, as reﬂected by
the 1.5–3.3 and 1.5–1.8 times higher IC50 values of 8 and 10
in comparison with 9 and 11, respectively (Table 3, Fig. 6).
A comparison of the indolo[3,2-c]quinoline derivatives
with the indolo[3,2-d]benzazepine derivatives reveals that
the IC50 values of the former are all in the high nanomolar
range, whereas those of the latter are mostly in the low
micromolar range. The cytotoxicities of uncomplexed
derivatives L
2 and L
4 differ by factors of 41–89, depending
on the cell line. The differences are smaller but still pro-
nounced in the case of the ruthenium complexes (factors of
3–13 for the couple 5/9) and the osmium complexes (fac-
tors of 9–26 and 4.5–15 for the couples 6/10 and 7/11,
respectively) (Fig. 7).
DNA intercalation
The intercalation of compounds L
2, L
4, 7, and 11 into
DNA was assessed by treating salmon sperm DNA with
methyl green and measuring the competitive replacement
of methyl green by the compounds after incubation for 2 h
through the decrease of the optical density at 642 nm.
Osmium indolo[3,2-d]benzazepine complex 11 and metal-
free indolobenzazepine L
4 show a certain intercalating
Table 3 Cytotoxicity of indoloquinoline and indolobenzazepine
derivatives, their osmium(II) and ruthenium(II) arene complexes, and
ﬂavopiridol in three human cancer cell lines
Compound IC50 (lM)
a
CH1 SW480 A549
L
2 0.51 ± 0.05 0.28 ± 0.01 0.92 ± 0.18
5 0.44 ± 0.03 0.23 ± 0.01 0.50 ± 0.05
6 0.39 ± 0.04 0.22 ± 0.03 0.82 ± 0.06
7 0.44 ± 0.07 0.27 ± 0.003 0.58 ± 0.10
L
4 21 ± 32 5 ± 14 4 ± 1
8 4.3 ± 0.4 5.7 ± 0.3 9.7 ± 1.6
9 1.3 ± 0.1 2.8 ± 0.2 6.5 ± 1.0
10 3.5 ± 0.1 5.8 ± 0.2 13 ± 0.5
11 2.0 ± 0.6 3.6 ± 0.3 8.8 ± 0.3
Flavopiridol 0.029 ± 0.005 0.070 ± 0.004 0.13 ± 0.01
a The 50% inhibitory concentrations (mean ± standard deviations
from at least three independent experiments), as obtained by the MTT
assay (continuous exposure for 96 h)
Fig. 5 Concentration–effect curves of indoloquinoline derivative L
2
in comparison with ruthenium complex 5 and osmium complexes 6
and 7 in the human cancer cell lines A549 (a), SW480 (b) and CH1
(c), as obtained by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) assay (continuous exposure for 96 h)
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123capacity, which hardly exceeds 50% replacement of methyl
green even at the highest concentration tested, however.
The indoloquinoline compounds L
2 and 7 replace methyl
green even more efﬁciently (about 90%) than the well
known intercalating agent ethidium bromide (Fig. 8),
adding another molecular effect potentially relevant for
cytotoxicity. These results are not unexpected, given the
planar structure of the indoloquinolines, which should ﬁt
better between the nucleotides of DNA than the folded
indolobenzazepines, and considering that benzoindolo[3,2-
c]quinolines have been previously reported to intercalate
into DNA [51].
Fig. 6 Concentration–effect curves of indolobenzazepine derivative
L
4 in comparison with ruthenium complexes 8 and 9 and osmium
complexes 10 and 11 in the human cancer cell lines A549 (a), SW480
(b), and CH1 (c), as obtained by the MTT assay (continuous exposure
for 96 h)
Fig. 7 Concentration–effect curves of osmium complexes 6, 7, 10,
and 11 in comparison with uncomplexed ligands L
2 and L
4 in the
human cancer cell lines A549 (a), SW480 (b), and CH1 (c), as
obtained by the MTT assay (continuous exposure for 96 h)
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Measurements of kinase activity of recombinant cdk/cyclin
complexes after exposure to indoloquinoline L
2, indo-
lobenzazepine derivative L
4, and the corresponding
osmium complexes 7 and 11 were performed in the pres-
ence of (c-
32P)ATP and histone H1 as the substrate for
phosphorylation. Generally, the activity of cdk2/cyclin E
was affected by the test compounds (including the cdk
inhibitor ﬂavopiridol, which was used as a reference) to a
higher degree than that of cdk1/cyclin B, except for 11,
which inhibits both kinases to nearly equal extent. Whereas
the IC50 value for cdk1/cyclin B inhibition was only
reached within the concentration range up to 100 lM in the
case of 11 (90 lM), those for cdk2/cyclin E inhibition
decrease in the following rank order: 11 (100 lM)[L
4
(73 lM)[L
2 (70 lM)[7 (13 lM). Thus, the inhibitory
potency of L
2 resembles that of L
4, despite the 2 orders of
magnitude higher cytotoxicity, strongly suggesting that
other molecular effects account for the increased cytotox-
icity. Complexation with osmium has different conse-
quences for kinase inhibition. Whereas complex 7 inhibits
cdk2/cyclin E to a somewhat higher degree than uncom-
plexed indoloquinoline L
2, comparison of complex 11 with
indolobenzazepine derivative L
4 reveals an increased
inhibitory activity in cdk1/cyclin B only (Figs. 9, 10).
Thus, all of the four selected compounds are capable of
inhibiting cdk activity in vitro. As the inhibitory potencies
do not parallel the cytotoxicities, which differ greatly, it is
unlikely that cdk2 inhibition is the crucial effect accounting
for their cytotoxicity, however. When considering that the
concentration required even for inhibition of cdk2/cyclin E
appears rather high, one should keep in mind that in the
case of ﬂavopiridol, a prototypic cdk inhibitor, the IC50
value for cdk2/cyclin E inhibition (approximately 0.3 lM)
is also higher than those in the MTT assay (0.029–
0.13 lM). This apparent discrepancy may be explained by
the facts that ﬂavopiridol inhibits other kinases, such as
cdk4/cyclin D and cdk6/cyclin D [52], cdk7 [53], and cdk9
[54], with much higher potency and that the inhibition of
just cdk2 is generally not sufﬁcient for the induction of cell
death, as demonstrated by Berthet et al. [55] in cdk2-
knockout mice.
Cell cycle effects
To study changes in cell cycle distribution induced by L
2,
L
4, 7, and 11, exponentially growing A549 cells were
treated with these compounds in various concentrations for
24 h, then stained with propidium iodide and analyzed for
their DNA content by ﬂow cytometry. These experiments
showed that indoloquinoline L
2 and the corresponding
osmium complex 7 have comparable effects on the cell
cycle, which vary strongly depending on the concentration
(Fig. 11). Whereas 1 lM concentration of these com-
pounds induces a marked G2/M arrest, the S-phase fraction
increases to more than double the amount at the expense of
both the G0/G1 and G2/M fractions at concentrations of
4 lM. No S-phase arrest is discernible at concentrations of
Fig. 8 Replacement of methyl green from salmon sperm DNA as a
measure for DNA intercalation, using ethidium bromide (EtBr)a sa
positive control (mean ± standard deviations)
Fig. 9 Concentration-dependent inhibition of cdk2/cyclin E activity
(mean ± standard deviations) by indoloquinoline L
2, indolobenz-
azepine derivative L
4, and the corresponding osmium complexes 7
and 11, in vitro. Flavopiridol (FP) was used as a positive control
Fig. 10 Concentration-dependent inhibition of cdk1/cyclin B activity
(mean ± standard deviations) by indoloquinoline L
2, indolobenz-
azepine derivative L
4, and the corresponding osmium complexes 7
and 11, in vitro. Flavopiridol (FP) was used as a positive control
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the S phase. At the highest concentration tested (64 lM),
the phase distributions converge to that of the control,
suggestive of a loss of phase speciﬁcity. Thus, the cellular
effects of the highly cytotoxic indoloquinolines cause
strong cell cycle perturbations, even though the results of
the kinase inhibition experiments described earlier do not
support cdks as their principal targets. In sharp contrast,
indolobenzazepine derivative L
4 and the corresponding
osmium complex 11 exert very minor effects on the cell
cycle, despite their similar cdk-inhibitory potencies in the
cell-free setting.
Conclusions
The results presented herein establish synthetic access to a
new family of metal-based indolo[3,2-c]quinolines, in
addition to a closely related class of metal-based indolo[3,2-
d]benzazepines (paullones), extending our previous work
on the latter class of compounds. A number of ruthenium(II)
arene and osmium(II) arene complexes with indolo[3,2-c]-
quinolines and indolo[3,2-d]benzazepines have been pre-
pared, enabling a comparative estimation of the solubility,
thermal stability, hydrolytic behavior, and antiproliferative
activity of the two closely related classes of organic mole-
cules. The compounds inhibit cancer cell proliferation, and
structure–activity relationships have been elucidated. In
particular, replacement of the seven-membered nonplanar
azepine ring in indolo[3,2-d]benzazepines by a six-mem-
bered ﬂat ring in indolo[3,2-c]quinolines resulted in a
pronounced enhancement of cytotoxicity. Metal-free
indolo[3,2-c]quinolines revealed IC50 values in the high
nanomolar range, whereas closely related indolo[3,2-d]-
benzazepines had IC50 values in the low micromolar range.
Thismightbeduetothehigherabilityoftheﬂatindolo[3,2-c]-
quinoline backbone to intercalate into DNA, in contrast to
the folded molecule structure of the related indolo[3,2-d]-
benzazepine derivatives. Complexation of indolo[3,2-c]-
quinolines with ruthenium(II) arene and osmium(II) arene
scaffolds results in a slight (if at all) increase of antipro-
liferative activity, with a very small difference between
ruthenium and osmium, whereas binding of indo-
lobenzazepine L
4 to ruthenium(II) and osmium(II) gives
rise to a 6.8–16-fold and a ﬁvefold to tenfold enhancement
of cytotoxic potency, respectively, depending on the cell
line.Differenteffectsofmetalcoordinationforindolo[3,2-c]-
quinolines and indolo[3,2-d]benzazepines in terms of
cytotoxicity might be a result of higher kinetic lability
of metal-based indolo[3,2-c]quinolines in cell culture
Fig. 11 Concentration-dependent impact of L
2, L
4, 7, and 11 on the cell cycle distribution of A549 cells after exposure for 24 h. The DNA
content of cells stained with propidium iodide was analyzed by ﬂow cytometry
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evidence for the increased lability toward ligand-exchange
reactions at the metal center of metal-based indolo[3,2-c]-
quinolines compared with metallated indolo[3,2-d]-
benzazepines. Terminal dimethylation of the ethane-1,2-di-
amine side chain has little effect on biological activity of
ruthenium and osmium complexes, being slightly more
favorable in the case of metal-based indolobenzazepines.
Cell cycle perturbations are pronounced in cancer cells
treated with the indoloquinolines, but are almost negligible
in the case of the paullone derivatives. In cell-free exper-
iments, all compounds studied proved to be capable of
inhibition of cdk activity, as exempliﬁed by cdk2/cyclin E.
However, a synopsis of structure–activity relationships
with regard to cytotoxicity, cell cycle effects and kinase
inhibition does not support cdk1 and cdk2 as the principal
targets of these compounds.
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